## Richard B Lipton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8450808/publications.pdf

Version: 2024-02-01

458 papers 29,574 citations

83 h-index 155 g-index

547 all docs

547 docs citations

times ranked

547

20201 citing authors

#	Article	IF	Citations
1	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
2	Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II. Headache, 2001, 41, 646-657.	3.9	1,933
3	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
4	Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Populationâ€Based Study. Headache, 2008, 48, 1157-1168.	3.9	683
5	Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ: British Medical Journal, 2009, 339, b3914-b3914.	2.3	648
6	Migraine Diagnosis and Treatment: Results From the American Migraine Study II. Headache, 2001, 41, 638-645.	3.9	631
7	Prevalence of Frequent Headache in a Population Sample. Headache, 1998, 38, 497-506.	3.9	560
8	Cutaneous allodynia in the migraine population. Annals of Neurology, 2008, 63, 148-158.	5.3	461
9	Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurology, The, 2010, 9, 373-380.	10.2	413
10	Classification of Daily and Nearâ€Daily Headaches: Proposed Revisions to the IHS Criteria. Headache, 1994, 34, 1-7.	3.9	382
11	Migraine. Neurologic Clinics, 2019, 37, 631-649.	1.8	358
12	Medical Consultation for Migraine: Results From the American Migraine Study. Headache, 1998, 38, 87-96.	3.9	340
13	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurology, The, 2014, 13, 1100-1107.	10.2	333
14	Stratified Care vs Step Care Strategies for Migraine. JAMA - Journal of the American Medical Association, 2000, 284, 2599.	7.4	318
15	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	2.6	317
16	Migraine: epidemiology and systems of care. Lancet, The, 2021, 397, 1485-1495.	13.7	310
17	Migraine and its psychiatric comorbidities. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 741-749.	1.9	298
18	Information About Migraine Disability Influences Physicians' Perceptions of Illness Severity and Treatment Needs. Headache, 2001, 41, 343-350.	3.9	282

#	Article	IF	CITATIONS
19	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia, 2018, 38, 815-832.	3.9	245
20	Excessive acute migraine medication use and migraine progression. Neurology, 2008, 71, 1821-1828.	1.1	244
21	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurology, The, 2015, 14, 1081-1090.	10.2	236
22	Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet, The, 2019, 394, 737-745.	13.7	236
23	Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology, 2020, 94, e1365-e1377.	1.1	236
24	Prevalence of neck pain in migraine and tension-type headache: A population study. Cephalalgia, 2015, 35, 211-219.	3.9	235
25	Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine. New England Journal of Medicine, 2019, 381, 142-149.	27.0	235
26	Ubrogepant for the Treatment of Migraine. New England Journal of Medicine, 2019, 381, 2230-2241.	27.0	230
27	Nerve growth factor prevents toxic neuropathy in mice. Annals of Neurology, 1991, 29, 87-90.	5 <b>.</b> 3	228
28	Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention. Headache, 2015, 55, 103-122.	3.9	227
29	The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration. PLoS ONE, 2015, 10, e0142388.	2.5	225
30	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurology, The, 2015, 14, 1091-1100.	10.2	221
31	Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology, 2015, 84, 688-695.	1.1	219
32	Assessment of Migraine Disability Using the Migraine Disability Assessment (MIDAS) Questionnaire: A Comparison of Chronic Migraine With Episodic Migraine. Headache, 2003, 43, 336-342.	3.9	218
33	A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia, 2016, 36, 887-898.	3.9	218
34	Age-dependent prevalence and clinical features of migraine. Neurology, 2006, 67, 246-251.	1.1	216
35	What Do Patients With Migraine Want From Acute Migraine Treatment?. Headache, 2002, 42, 3-9.	3.9	214
36	Depression and risk of transformation of episodic to chronic migraine. Journal of Headache and Pain, 2012, 13, 615-624.	6.0	214

#	Article	IF	Citations
37	Screening for Dementia by Telephone Using the Memory Impairment Screen. Journal of the American Geriatrics Society, 2003, 51, 1382-1390.	2.6	208
38	The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia, 2015, 35, 563-578.	3.9	203
39	Migraine Progression: A Systematic Review. Headache, 2019, 59, 306-338.	3.9	198
40	Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine. JAMA - Journal of the American Medical Association, 2019, 322, 1887.	7.4	193
41	Clinical course in migraine. Neurology, 2008, 71, 848-855.	1.1	190
42	A change point model for estimating the onset of cognitive decline in preclinical Alzheimer's disease. Statistics in Medicine, 2000, 19, 1555-1566.	1.6	188
43	Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet, The, 2021, 397, 51-60.	13.7	178
44	Reliability and Validity of Ambulatory Cognitive Assessments. Assessment, 2018, 25, 14-30.	3.1	177
45	Headache Impact of Chronic and Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study. Headache, 2012, 52, 3-17.	3.9	174
46	Medication Use and Disability Among Migraineurs: A National Probability Sample Survey. Headache, 1992, 32, 223-228.	3.9	171
47	ASSESSMENT OF COGNITIVE FUNCTION OF THE ELDERLY POPULATION: EFFECTS OF DARIFENACIN. Journal of Urology, 2005, 173, 493-498.	0.4	169
48	An Update on the Epidemiology of Migraine. Headache, 1994, 34, 319-328.	3.9	167
49	Pathological markers associated with normal aging and dementia in the elderly. Annals of Neurology, 1993, 34, 566-573.	5.3	166
50	Female advantage in verbal memory. Neurology, 2016, 87, 1916-1924.	1.1	163
51	Tracing transformation. Neurology, 2009, 72, S3-7.	1.1	161
52	Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache, 2016, 56, 821-834.	3.9	160
53	Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. Journal of Headache and Pain, 2017, $18, 101$ .	6.0	158
54	Personality predicts mortality risk: An integrative data analysis of 15 international longitudinal studies. Journal of Research in Personality, 2017, 70, 174-186.	1.7	155

#	Article	IF	CITATIONS
55	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia, 2019, 39, 687-710.	3.9	154
56	Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurology, The, 2019, 18, 891-902.	10.2	151
57	Barriers to the Diagnosis and Treatment of Migraine: Effects of Sex, Income, and Headache Features. Headache, 2013, 53, 81-92.	3.9	144
58	Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. Journal of Headache and Pain, 2020, 21, 23.	6.0	143
59	Transcranial Magnetic Simulation in the Treatment of Migraine. Neurotherapeutics, 2010, 7, 204-212.	4.4	139
60	Familial risk of migraine: A population-based study. Annals of Neurology, 1997, 41, 166-172.	5.3	137
61	Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache, 2019, 59, 1286-1299.	3.9	135
62	The migraine postdrome. Neurology, 2016, 87, 309-313.	1.1	134
63	Motoric cognitive risk syndrome. Neurology, 2014, 83, 2278-2284.	1.1	133
64	Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy. Neurology, 2016, 86, 1368-1376.	1.1	131
65	Examination of Unmet Treatment Needs Among Persons With Episodic Migraine: Results of the <scp>A</scp> merican <scp>M</scp> igraine <scp>P</scp> revalence and <scp>P</scp> revention ( <scp>AMPP</scp> ) Study. Headache, 2013, 53, 1300-1311.	3.9	128
66	A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headacheâ€Related Disability. Headache, 2016, 56, 1280-1289.	3.9	127
67	Atogepant for the Preventive Treatment of Migraine. New England Journal of Medicine, 2021, 385, 695-706.	27.0	126
68	Reduction in perceived stress as a migraine trigger. Neurology, 2014, 82, 1395-1401.	1.1	123
69	Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. Mayo Clinic Proceedings, 2016, 91, 596-611.	3.0	123
70	The Effects of Stress on Cognitive Aging, Physiology and Emotion (ESCAPE) Project. BMC Psychiatry, 2015, 15, 146.	2.6	120
71	Age-related cognitive decline and associations with sex, education and apolipoprotein E genotype across ethnocultural groups and geographic regions: a collaborative cohort study. PLoS Medicine, 2017, 14, e1002261.	8.4	120
72	The epidemiology of migraine. The American Journal of Medicine: Supplement, 2005, 118, 3-10.	1.6	115

#	Article	IF	CITATIONS
73	A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia, 2018, 38, 1038-1048.	3.9	113
74	Overuse of acute migraine medications and migraine chronification. Current Pain and Headache Reports, 2009, 13, 301-307.	2.9	109
75	Differential association of left and right hippocampal volumes with verbal episodic and spatial memory in older adults. Neuropsychologia, 2016, 93, 380-385.	1.6	108
76	Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia, 2019, 39, 1075-1085.	3.9	107
77	Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences. Headache, 2018, 58, 1408-1426.	3.9	106
78	Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 996-1001.	1.9	105
79	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia, 2020, 40, 1026-1044.	3.9	105
80	Opioid Use and Dependence Among Persons With Migraine: Results of the AMPP Study. Headache, 2012, 52, 18-36.	3.9	103
81	Epidemiology and Economic Impact of Migraine. Current Medical Research and Opinion, 2001, 17, s4-12.	1.9	102
82	Evaluation of Chronic Daily Headache—Comparison to Criteria for Chronic Tension-Type Headache. Cephalalgia, 1992, 12, 365-368.	3.9	93
83	Aerobic Exercise for Reducing Migraine Burden: Mechanisms, Markers, and Models of Change Processes. Headache, 2016, 56, 357-369.	3.9	90
84	Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. Journal of Headache and Pain, 2018, 19, 38.	6.0	88
85	Determinants of cognitive performance and decline in 20 diverse ethno-regional groups: A COSMIC collaboration cohort study. PLoS Medicine, 2019, 16, e1002853.	8.4	86
86	Methodological Issues in Studying Trigger Factors and Premonitory Features of Migraine. Headache, 2014, 54, 1661-1669.	3.9	84
87	Neurocognitive Function Among Middle-aged and Older Hispanic/Latinos: Results from the Hispanic Community Health Study/Study of Latinos. Archives of Clinical Neuropsychology, 2015, 30, 68-77.	0.5	84
88	Erenumab in chronic migraine. Neurology, 2019, 92, e2250-e2260.	1.1	83
89	Aspirin Is Efficacious for the Treatment of Acute Migraine. Headache, 2005, 45, 283-292.	3.9	80
90	Arterial Stenosis in Migraine: Spasm or Arteriopathy?. Headache, 1990, 30, 52-61.	3.9	78

#	Article	IF	CITATIONS
91	Ten Lessons on the Epidemiology of Migraine. Headache, 2007, 47, S2-S9.	3.9	78
92	Acute headache diagnosis in pregnant women. Neurology, 2015, 85, 1024-1030.	1.1	78
93	Roles of hippocampal subfields in verbal and visual episodic memory. Behavioural Brain Research, 2017, 317, 157-162.	2.2	78
94	Estimation of bivariate measurements having different change points, with application to cognitive ageing. Statistics in Medicine, 2001, 20, 3695-3714.	1.6	77
95	Motoric Cognitive Risk Syndrome and Falls Risk: A Multi-Center Study. Journal of Alzheimer's Disease, 2016, 53, 1043-1052.	2.6	77
96	Tension-type headache. Nature Reviews Disease Primers, 2021, 7, 24.	30.5	75
97	Trajectories of Big Five Personality Traits: A Coordinated Analysis of 16 Longitudinal Samples. European Journal of Personality, 2020, 34, 301-321.	3.1	74
98	Trends in Dementia Incidence in a Birth Cohort Analysis of the Einstein Aging Study. JAMA Neurology, 2017, 74, 1345.	9.0	73
99	Caffeine in the management of patients with headache. Journal of Headache and Pain, 2017, 18, 107.	6.0	<b>7</b> 3
100	Psychological Factors Associated With Chronic Migraine and Severe Migraineâ€Related Disability: An Observational Study in a Tertiary Headache Center. Headache, 2017, 57, 593-604.	3.9	71
101	Aspartame as a Dietary Trigger of Headache. Headache, 1989, 29, 90-92.	3.9	70
102	Migraine headache: Epidemiology and health care utilization. Cephalalgia, 1993, 13, 41-46.	3.9	67
103	Recalled maltreatment, migraine, and tension-type headache. Neurology, 2015, 84, 132-140.	1.1	66
104	OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program. Cephalalgia, 2016, 36, 899-908.	3.9	66
105	Hippocampal volume and cingulum bundle fractional anisotropy are independently associated with verbal memory in older adults. Brain Imaging and Behavior, 2016, 10, 652-659.	2.1	66
106	Predicting Inadequate Response to Acute Migraine Medication: Results From the <scp>A</scp> merican Migraine Prevalence and Prevention ( <scp>AMPP</scp> ) Study. Headache, 2016, 56, 1635-1648.	3.9	64
107	Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study. Alzheimer's Research and Therapy, 2020, 12, 167.	6.2	64
108	Sleep Disorders Among People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache, 2019, 59, 32-45.	3.9	63

#	Article	IF	Citations
109	The Burden of Migraine. Pharmacoeconomics, 1994, 6, 215-221.	3.3	62
110	Does Mindfulnessâ€Based Cognitive Therapy for Migraine Reduce Migraineâ€Related Disability in People with Episodic and Chronic Migraine? A Phase 2b Pilot Randomized Clinical Trial. Headache, 2019, 59, 1448-1467.	3.9	62
111	Comorbid pain and migraine chronicity. Neurology, 2017, 89, 461-468.	1.1	61
112	Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study. Headache, 2020, 60, 416-429.	3.9	61
113	Burden of migraine related to menses: results from the AMPP study. Journal of Headache and Pain, 2015, 16, 24.	6.0	60
114	Migraine progression in subgroups of migraine based on comorbidities. Neurology, 2019, 93, e2224-e2236.	1.1	60
115	Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology, 2020, 94, e2121-e2125.	1.1	60
116	Frequency and Burden of Headacheâ€Related Nausea: Results From the <scp>A</scp> merican <scp>M</scp> igraine <scp>P</scp> revalence and <scp>P</scp> revention ( <scp>AMPP</scp> ) Study. Headache, 2013, 53, 93-103.	3.9	59
117	Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI. Neurology, 2019, 93, e1881-e1889.	1.1	59
118	In-office Discussions of Migraine: Results from the American Migraine Communication Study. Journal of General Internal Medicine, 2008, 23, 1145-1151.	2.6	57
119	FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. Headache, 2019, 59, 1700-1713.	3.9	55
120	Free and cued selective reminding and selective reminding in the elderly. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 643-654.	1.3	54
121	Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. Headache, 2019, 59, 1310-1323.	3.9	54
122	Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. Headache, 2020, 60, 1734-1742.	3.9	54
123	Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study. Cephalalgia, 2011, 31, 18-30.	3.9	53
124	A Gray Matter Volume Covariance Network Associated with the Motoric Cognitive Risk Syndrome: A Multicohort MRI Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 884-889.	3.6	53
125	Electronic behavioral interventions for headache: a systematic review. Journal of Headache and Pain, 2016, 17, 51.	6.0	52
126	Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: Results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia, 2010, 30, 1336-1345.	3.9	51

#	Article	IF	Citations
127	Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. International Journal of General Medicine, 2015, 8, 79.	1.8	51
128	Proposed new diagnostic criteria for chronic migraine. Cephalalgia, 2020, 40, 399-406.	3.9	50
129	Aging, encoding specificity, and memory change in the Double Memory Test. Journal of the International Neuropsychological Society, 1995, 1, 483-493.	1.8	49
130	Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example. Journal of Pain, 2015, 16, 164-175.	1.4	49
131	Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study. Headache, 2017, 57, 1026-1040.	3.9	49
132	Apathy and depressive symptoms in older people and incident myocardial infarction, stroke, and mortality: a systematic review and meta-analysis of individual participant data. Clinical Epidemiology, 2018, Volume 10, 363-379.	3.0	49
133	The effect of dementia risk factors on comparative and diagnostic selective reminding norms. Journal of the International Neuropsychological Society, 1997, 3, 317-326.	1.8	48
134	Exceptional Parental Longevity Associated with Lower Risk of Alzheimer's Disease and Memory Decline. Journal of the American Geriatrics Society, 2010, 58, 1043-1049.	2.6	48
135	Social Support Buffers the Impact of Depressive Symptoms on Life Satisfaction in Old Age. Clinical Gerontologist, 2016, 39, 139-157.	2.2	48
136	Characterizing opioid use in a US population with migraine. Neurology, 2020, 95, e457-e468.	1.1	48
137	Perceived Stress Is Differentially Related to Hippocampal Subfield Volumes among Older Adults. PLoS ONE, 2016, 11, e0154530.	2.5	48
138	Migraine in the Triptan Era: Lessons From Epidemiology, Pathophysiology, and Clinical Science. Headache, 2009, 49, S21-33.	3.9	47
139	Experts' opinion about the primary headache diagnostic criteria of the ICHD-3rd edition beta in children and adolescents. Journal of Headache and Pain, 2017, 18, 109.	6.0	47
140	Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache, 2020, 60, 2340-2356.	3.9	47
141	MRI-defined White Matter Microstructural Alteration Associated with Soccer Heading Is More Extensive in Women than Men. Radiology, 2018, 289, 478-486.	7.3	46
142	Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. Journal of Headache and Pain, 2016, 17, 106.	6.0	45
143	Motoric cognitive risk syndrome and predictors of transition to dementia: A multicenter study. Alzheimer's and Dementia, 2019, 15, 870-877.	0.8	45
144	Ubrogepant, an Acute Treatment for Migraine, Improved Patientâ€Reported Functional Disability and Satisfaction in 2 Singleâ€Attack Phase 3 Randomized Trials, ACHIEVE I and II. Headache, 2020, 60, 686-700.	3.9	45

#	Article	IF	CITATIONS
145	The Temporal Relationship between Pain Intensity and Pain Interference and Incident Dementia. Current Alzheimer Research, 2019, 16, 109-115.	1.4	44
146	Chronic versus episodic migraine: The 15â€day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache, 2021, 61, 992-1003.	3.9	44
147	Behavioral Weight Loss Intervention for Migraine: A Randomized Controlled Trial. Obesity, 2018, 26, 81-87.	3.0	43
148	A Coordinated Multi-study Analysis of the Longitudinal Association Between Handgrip Strength and Cognitive Function in Older Adults. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2021, 76, 229-241.	3.9	43
149	Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study. Headache, 2022, 62, 122-140.	3.9	43
150	Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM). Cephalalgia, 2016, 36, 203-215.	3.9	42
151	Negative and positive affect as predictors of inflammation: Timing matters. Brain, Behavior, and Immunity, 2018, 74, 222-230.	4.1	42
152	The Effect of Psychiatric Comorbidities on Headacheâ€Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache, 2020, 60, 1683-1696.	3.9	42
153	Reliability in headache diagnosis. Cephalalgia, 1993, 13, 29-33.	3.9	41
154	Fremanezumab for preventive treatment of migraine. Neurology, 2018, 91, e1152-e1165.	1.1	40
155	Barriers to Behavioral Treatment Adherence for Headache: An Examination of Attitudes, Beliefs, and Psychiatric Factors. Headache, 2019, 59, 19-31.	3.9	40
156	Myocardial Ischemia Related to Ergot Alkaloids: A Case Report and Literature Review. Headache, 1991, 31, 446-450.	3.9	39
157	Effect of Rizatriptan and Other Triptans on the Nausea Symptom of Migraine: A Post Hoc Analysis. Headache, 2001, 41, 754-763.	3.9	38
158	A migraine management training program for primary care providers: An overview of a survey and pilot study findings, lessons learned, and considerations for further research. Headache, 2016, 56, 725-740.	3.9	38
159	Heading Frequency Is More Strongly Related to Cognitive Performance Than Unintentional Head Impacts in Amateur Soccer Players. Frontiers in Neurology, 2018, 9, 240.	2.4	38
160	Gray matter volume covariance patterns associated with gait speed in older adults: a multi-cohort MRI study. Brain Imaging and Behavior, 2019, 13, 446-460.	2.1	38
161	Predicting dementia with routine care EMR data. Artificial Intelligence in Medicine, 2020, 102, 101771.	6.5	38
162	Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin geneâ€'related peptideâ€targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drugâ€"drug interaction study. Headache, 2021, 61, 642-652.	3.9	37

#	Article	IF	CITATIONS
163	Nativity differences in allostatic load by age, sex, and Hispanic background from the Hispanic Community Health Study/Study of Latinos. SSM - Population Health, 2016, 2, 416-424.	2.7	36
164	Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. Journal of Medical Economics, 2018, 21, 666-675.	2.1	36
165	Depressive Symptoms Predict Incident Dementia in a Community Sample of Older Adults: Results From the Einstein Aging Study. Journal of Geriatric Psychiatry and Neurology, 2019, 32, 97-103.	2.3	36
166	Hippocampal subfields differentially correlate with chronic pain in older adults. Brain Research, 2014, 1573, 54-62.	2,2	35
167	Cerebral Hemodynamics in the Elderly. Journal of Ultrasound in Medicine, 2016, 35, 1907-1914.	1.7	35
168	Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. Journal of Headache and Pain, 2020, 21, 20.	6.0	35
169	Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study. Headache, 2021, 61, 628-641.	3.9	35
170	Sex Differences in the Relationship between Depressive Symptoms and Risk of Amnestic Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2017, 25, 13-22.	1.2	34
171	Epidemiology of migraine in men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Cephalalgia, 2019, 39, 296-305.	3.9	34
172	Rates and reasons for discontinuation of triptans and opioids in episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. Journal of the Neurological Sciences, 2013, 326, 10-17.	0.6	33
173	Association Between Obesity and Migraine in Women. Current Pain and Headache Reports, 2017, 21, 41.	2.9	33
174	Memory Binding Test Distinguishes Amnestic Mild Cognitive Impairment and Dementia from Cognitively Normal Elderly. Archives of Clinical Neuropsychology, 2017, 32, 29-39.	0.5	33
175	Systematic review of outcomes and endpoints in acute migraine clinical trials. Headache, 2021, 61, 263-275.	3.9	33
176	Improving the Classification of Migraine Subtypes: An Empirical Approach Based on Factor Mixture Models in the <scp>A</scp> merican <scp>M</scp> igraine <scp>P</scp> revalence and <scp>P</scp> revention ( <scp>AMPP</scp> ) Study. Headache, 2014, 54, 830-849.	3.9	32
177	Spatial navigation and risk of cognitive impairment: A prospective cohort study. Alzheimer's and Dementia, 2017, 13, 985-992.	0.8	32
178	Does Scopolamine Directly Impair Memory?. Journal of Cognitive Neuroscience, 1989, 1, 327-335.	2.3	31
179	Association of psychological, cognitive, and functional variables with self-reported executive functioning in a sample of nondemented community-dwelling older adults. Applied Neuropsychology Adult, 2017, 24, 364-375.	1.2	31
180	DFNâ€02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Doubleâ€Blind, Placeboâ€Controlled Study. Headache, 2018, 58, 676-687.	3.9	31

#	Article	IF	CITATIONS
181	Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache, 2019, 59, 1762-1772.	3.9	31
182	Migraine MLTâ€Down: An Unusual Presentation of Migraine in Patients With Aspartameâ€Triggered Headaches. Headache, 2001, 41, 899-901.	3.9	30
183	Reliability and Validity of the Migraine Disability Assessment Scale among Migraine and Tension Type Headache in Iranian Patients. BioMed Research International, 2014, 2014, 1-7.	1.9	30
184	Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale. Headache, 2017, 57, 570-585.	3.9	30
185	Smartphoneâ€Delivered Progressive Muscle Relaxation for the Treatment of Migraine in Primary Care: A Randomized Controlled Trial. Headache, 2020, 60, 2232-2246.	3.9	30
186	Sumatriptan Relieves Migrainelike Headaches Associated With Carbon Monoxide Exposure. Headache, 1997, 37, 392-395.	3.9	29
187	Factors Related to Migraine Patients' Decisions to Initiate Behavioral Migraine Treatment Following a Headache Specialist's Recommendation: A Prospective Observational Study. Pain Medicine, 2018, 19, 2274-2282.	1.9	29
188	Post-Traumatic Stress Disorder After Traumatic Brain Injury—A Systematic Review and Meta-Analysis. Neurological Sciences, 2020, 41, 2737-2746.	1.9	29
189	Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Cephalalgia, 2022, 42, 3-11.	3.9	29
190	Headaches in Hospitalized Cocaine Users. Headache, 1989, 29, 225-228.	3.9	28
191	Walking While Talking and Risk of Incident Dementia. American Journal of Geriatric Psychiatry, 2018, 26, 580-588.	1.2	28
192	Systematic review of outcomes and endpoints in preventive migraine clinical trials. Headache, 2021, 61, 253-262.	3.9	28
193	Chronic Kidney Disease in Non-Diabetic Older Adults: Associated Roles of the Metabolic Syndrome, Inflammation, and Insulin Resistance. PLoS ONE, 2015, 10, e0139369.	2.5	27
194	Comparison of "Word―vs. "Picture―version of the Free and Cued Selective Reminding Test (FCSRT) in older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 94-100.	2.4	27
195	Predicting Amyloid- $\hat{l}^2$ Levels in Amnestic Mild Cognitive Impairment Using Machine Learning Techniques. Journal of Alzheimer's Disease, 2020, 73, 1211-1219.	2.6	27
196	Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. Headache, 2021, 61, 662-672.	3.9	27
197	Optimizing Machine Learning Methods to Improve Predictive Models of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 71, 1027-1036.	2.6	26
198	Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study. Cephalalgia, 2019, 39, 873-882.	3.9	26

#	Article	IF	Citations
199	Psychiatric and cognitive comorbidities of persistent post-traumatic headache attributed to mild traumatic brain injury. Journal of Headache and Pain, 2021, 22, 83.	6.0	26
200	Evaluation of the Reliability, Validity, and Predictive Validity of the Subscales of the Perceived Stress Scale in Older Adults. Journal of Alzheimer's Disease, 2017, 59, 987-996.	2.6	25
201	Distinct inflammatory response patterns are evident among men and women with higher depressive symptoms. Physiology and Behavior, 2018, 184, 108-115.	2.1	25
202	Improving Medical Communication in Migraine Management: A Modified Delphi Study to Develop a Digital Migraine Tracker. Headache, 2018, 58, 1358-1372.	3.9	25
203	Costs of Acute Headache Medication Use and Productivity Losses Among Patients with Migraine: Insights from Three Randomized Controlled Trials. PharmacoEconomics - Open, 2019, 3, 411-417.	1.8	25
204	Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a <i>post-hoc</i> analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia, 2021, 41, 6-16.	3.9	25
205	Medication Overuse and Headache Burden. Neurology: Clinical Practice, 2021, 11, 216-226.	1.6	25
206	Variability in Cognitive Performance on Mobile Devices Is Sensitive to Mild Cognitive Impairment: Results From the Einstein Aging Study. Frontiers in Digital Health, 2021, 3, 758031.	2.8	25
207	Comparison of motor conduction abnormalities in lumbosacral radiculopathy and axonal polyneuropathy., 1999, 22, 1053-1057.		24
208	Experts' opinion about the pediatric secondary headaches diagnostic criteria of the ICHD-3 beta. Journal of Headache and Pain, 2017, 18, 113.	6.0	24
209	Two randomized migraine studies of galcanezumab. Neurology, 2019, 93, e508-e517.	1.1	24
210	Detecting biological heterogeneity patterns in ADNI amnestic mild cognitive impairment based on volumetric MRI. Brain Imaging and Behavior, 2020, 14, 1792-1804.	2.1	24
211	Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data. Journal of Primary Care and Community Health, 2020, 11, 215013272096368.	2.1	24
212	Diabetes, Cognitive Decline, and Mild Cognitive Impairment Among Diverse Hispanics/Latinos: Study of Latinos–Investigation of Neurocognitive Aging Results (HCHS/SOL). Diabetes Care, 2020, 43, 1111-1117.	8.6	24
213	Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. Cephalalgia, 2021, 41, 279-293.	3.9	24
214	Learning the full impact of migraine through patient voices: A qualitative study. Headache, 2021, 61, 1004-1020.	3.9	24
215	Looking to the Future: Research Designs for Study of Headache Disease Progression. Headache, 2008, 48, 58-66.	3.9	23
216	Memory Binding Test Predicts Incident Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 53, 1585-1595.	2.6	23

#	Article	IF	CITATIONS
217	APOE ε4 and the Influence of Sex, Age, Vascular Risk Factors, and Ethnicity on Cognitive Decline. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1863-1873.	3.6	23
218	Characterization of Neck Strength in Healthy Young Adults. PM and R, 2017, 9, 884-891.	1.6	22
219	Determining Thresholds for Meaningful Change for the Headache Impact Test (HITâ€6) Total and Itemâ€Specific Scores in Chronic Migraine. Headache, 2020, 60, 2003-2013.	3.9	22
220	Neck pain and headache after whiplash injury: a systematic review and meta-analysis. Pain, 2020, 161, 880-888.	4.2	22
221	Bidirectional Changes in Anisotropy Are Associated with Outcomes in Mild Traumatic Brain Injury. American Journal of Neuroradiology, 2016, 37, 1983-1991.	2.4	21
222	Measures of Functioning in Patients With Episodic Migraine: Findings From a Doubleâ€Blind, Randomized, Placeboâ€Controlled Phase 2b Trial With Galcanezumab. Headache, 2018, 58, 1225-1235.	3.9	21
223	Cardiovascular disease risk factor burden and cognition: Implications of ethnic diversity within the Hispanic Community Health Study/Study of Latinos. PLoS ONE, 2019, 14, e0215378.	2.5	21
224	Toward an Epidemiology of Refractory Migraine: Current Knowledge and Issues for Future Research. Headache, 2008, 48, 791-798.	3.9	20
225	Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headacheâ€Related Disability: Results From the American Migraine Prevalence and Prevention ( <scp>AMPP</scp> ) Study. Headache, 2015, 55, 825-839.	3.9	20
226	A Multi-study Coordinated Meta-analysis of Pulmonary Function and Cognition in Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1793-1804.	3.6	20
227	Patientâ€identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patientâ€centered outcome. Headache, 2021, 61, 766-776.	3.9	20
228	Glycemic control, cognitive function, and family support among middle-aged and older Hispanics with diabetes: The Hispanic Community Health Study/Study of Latinos. Diabetes Research and Clinical Practice, 2016, 117, 64-73.	2.8	19
229	Pain grade and sleep disturbance in older adults: evaluation the role of pain, and stress for depressed and nonâ€depressed individuals. International Journal of Geriatric Psychiatry, 2016, 31, 450-457.	2.7	19
230	Growth of Headache Research: A 1983–2014 bibliometric study. Cephalalgia, 2017, 37, 1299-1309.	3.9	19
231	Memory Binding Test Predicts Incident Dementia: Results from the Einstein Aging Study. Journal of Alzheimer's Disease, 2018, 62, 293-304.	2.6	19
232	Increases in Neuroticism May Be an Early Indicator of Dementia: A Coordinated Analysis. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2020, 75, 251-262.	3.9	19
233	Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Cephalalgia, 2020, 40, 639-649.	3.9	19
234	Associations of Apolipoprotein E ε4 Genotype and Ball Heading With Verbal Memory in Amateur Soccer Players. JAMA Neurology, 2020, 77, 419.	9.0	19

#	Article	IF	CITATIONS
235	Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. Cephalalgia, 2021, 41, 979-990.	3.9	19
236	Methodological Issues in Studying Rates and Predictors of Migraine Progression and Remission. Headache, 2013, 53, 930-934.	3.9	18
237	Reference Data of the Spanish Memory Binding Test in a Midlife Population from the ALFA STUDY (Alzheimer's and Family). Journal of Alzheimer's Disease, 2015, 48, 613-625.	2.6	18
238	Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study. Journal of Headache and Pain, 2019, 20, 10.	6.0	18
239	Core outcome set for preventive intervention trials in chronic and episodic migraine (COSMIG): an international, consensus-derived and multistakeholder initiative. BMJ Open, 2021, 11, e043242.	1.9	18
240	Transcutaneous and Percutaneous Neurostimulation for Headache Disorders. Headache, 2017, 57, 4-13.	3.9	17
241	Identification of Heterogeneous Cognitive Subgroups in Community-Dwelling Older Adults: A Latent Class Analysis of the Einstein Aging Study. Journal of the International Neuropsychological Society, 2018, 24, 511-523.	1.8	17
242	Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study. Journal of Headache and Pain, 2020, 21, 134.	6.0	17
243	A coordinated analysis of the associations among personality traits, cognitive decline, and dementia in older adulthood. Journal of Research in Personality, 2021, 92, 104100.	1.7	17
244	Association of Mediterranean Diet With Cognitive Decline Among Diverse Hispanic or Latino Adults From the Hispanic Community Health Study/Study of Latinos. JAMA Network Open, 2022, 5, e2221982.	<b>5.</b> 9	17
245	Event-related potential correlates of early processing in normal aging. International Journal of Neuroscience, 1995, 80, 371-382.	1.6	16
246	The global burden of migraine. Journal of Headache and Pain, 2003, 4, s3-s11.	6.0	16
247	Predicting Seizures: A Behavioral Approach. Neurologic Clinics, 2009, 27, 925-940.	1.8	16
248	Conceptualizing the relationship between chronic migraine and episodic migraine. Expert Review of Neurotherapeutics, 2009, 9, 1451-1454.	2.8	16
249	Adolescent Perspectives on the Burden of a Parent's Migraine: Results from the CaMEO Study. Headache, 2018, 58, 512-524.	3.9	16
250	Anxiety sensitivity and intentional avoidance of physical activity in women with probable migraine. Cephalalgia, 2019, 39, 1465-1469.	3.9	16
251	Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study. Journal of Headache and Pain, 2019, 20, 12.	6.0	16
252	Dizziness and vertigo during the prodromal phase and headache phase of migraine: A systematic review and meta-analysis. Cephalalgia, 2020, 40, 1095-1103.	3.9	16

#	Article	IF	Citations
253	A dedicated scholarly research program in an adult and pediatric neurology residency program. Neurology, 2017, 88, 1366-1370.	1.1	15
254	Association Between Vascular Pathology and Rate of Cognitive Decline Independent of Alzheimer's Disease Pathology. Journal of the American Geriatrics Society, 2017, 65, 1836-1841.	2.6	15
255	Passive Digital Signature for Early Identification of Alzheimer's Disease and Related Dementia. Journal of the American Geriatrics Society, 2020, 68, 511-518.	2.6	15
256	The relationship between hippocampal volume, chronic pain, and depressive symptoms in older adults. Psychiatry Research - Neuroimaging, 2019, 289, 10-12.	1.8	14
257	Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Qualityâ€ofâ€Life Questionnaire Version 2.1 Electronic Patientâ€Reported Outcome in Patients With Episodic and Chronic Migraine. Headache, 2019, 59, 756-774.	3.9	14
258	Efficacy, Tolerability, and Safety of DFNâ€15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Doubleâ€Blind, Placeboâ€Controlled Study. Headache, 2020, 60, 58-70.	3.9	14
259	Focus group findings on the migraine patient experience during research studies and ideas for future investigations. Cephalalgia, 2020, 40, 712-734.	3.9	14
260	Characterization of Acute Prescription Migraine Medication Use. Mayo Clinic Proceedings, 2020, 95, 709-718.	3.0	14
261	Patterns of Perceived Stress Throughout the Migraine Cycle: A Longitudinal Cohort Study Using Daily Prospective Diary Data. Headache, 2021, 61, 90-102.	3.9	14
262	Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 study. Quality of Life Research, 2021, 30, 931-943.	3.1	14
263	White matter hyperintensities and cognition across different Alzheimer's biomarker profiles. Journal of the American Geriatrics Society, 2021, 69, 1906-1915.	2.6	14
264	Is Healthy Neuroticism Associated with Longevity? A Coordinated Integrative Data Analysis. Collabra: Psychology, 2020, 6, .	1.8	14
265	Epidemiology of migraine. Current Pain and Headache Reports, 2001, 5, 189-194.	2.9	13
266	Introduction to the Special Series on the Chronification of Headache: Mechanisms, Risk Factors, and Behavioral Strategies Aimed at Primary and Secondary Prevention of Chronic Headache. Headache, 2008, 48, 5-6.	3.9	13
267	Healthcare resource utilization and direct costs associated with frequent nausea in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Journal of Medical Economics, 2013, 16, 490-499.	2.1	13
268	Class-Specific Incidence of All-Cause Dementia and Alzheimer's Disease: A Latent Class Approach. Journal of Alzheimer's Disease, 2018, 66, 347-357.	2.6	13
269	Subtypes Based on Neuropsychological Performance Predict Incident Dementia: Findings from the Rush Memory and Aging Project. Journal of Alzheimer's Disease, 2019, 67, 125-135.	2.6	13
270	Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study. Headache, 2020, 60, 2444-2453.	3.9	13

#	Article	IF	CITATIONS
271	Acute treatment patterns in patients with migraine newly initiating a triptan. Cephalalgia, 2020, 40, 437-447.	3.9	13
272	Underuse of Behavioral Treatments for Headache: a Narrative Review Examining Societal and Cultural Factors. Journal of General Internal Medicine, 2021, 36, 3103-3112.	2.6	13
273	Psychosocial Factors Associated with Cognitive Function Among Middle-Aged and Older Hispanics/Latinos: The Hispanic Community Health Study/Study of Latinos and its Sociocultural Ancillary Study. Journal of Alzheimer's Disease, 2021, 79, 433-449.	2.6	13
274	Positively Worded Subscale Score of the Perceived Stress Scale Is Associated with Cognitive Domain Function. Journal of Behavioral and Brain Science, 2017, 07, 311-324.	0.5	12
275	Recalled early life adversity and pain: the role of mood, sleep, optimism, and control. Journal of Behavioral Medicine, 2018, 41, 504-515.	2.1	12
276	Pain worsening with physical activity during migraine attacks in women with overweight/obesity: A prospective evaluation of frequency, consistency, and correlates. Cephalalgia, 2018, 38, 1707-1715.	3.9	12
277	Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients. Cephalalgia, 2019, 39, 465-476.	3.9	12
278	Framing potential for adverse effects of repetitive subconcussive impacts in soccer in the context of athlete and non-athlete controls. Brain Imaging and Behavior, 2021, 15, 882-895.	2.1	12
279	Stress Is Associated With Neurocognitive Function in Hispanic/Latino Adults: Results From HCHS/SOL Socio-Cultural Ancillary Study. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2021, 76, e122-e128.	3.9	12
280	Trajectories of frailty in aging: Prospective cohort study. PLoS ONE, 2021, 16, e0253976.	2.5	12
281	Health-related quality of life in tension-type headache: a population-based study. Scandinavian Journal of Pain, 2021, 21, 778-787.	1.3	12
282	The association of visual memory with hippocampal volume. PLoS ONE, 2017, 12, e0187851.	2.5	12
283	Development and validation of a novel patientâ Feported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary. Headache, 2022, 62, 89-105.	3.9	12
284	Oscillocusis: An Unusual Auditory Aura in Migraine. Headache, 1995, 35, 428-429.	3.9	11
285	CGRP antagonists in the acute treatment of migraine. Lancet Neurology, The, 2004, 3, 332.	10.2	11
286	A Brief Dietary Assessment Predicts Executive Dysfunction in an Elderly Cohort: Results from the Einstein Aging Study. Journal of the American Geriatrics Society, 2016, 64, e131-e136.	2.6	11
287	Naproxen for presymptomatic Alzheimer disease. Neurology, 2019, 92, 829-830.	1.1	11
288	Impact of the COVIDâ€19 pandemic on people living with migraine: Results of the MiCOAS qualitative study. Headache, 2022, 62, 284-293.	3.9	11

#	Article	IF	CITATIONS
289	Longitudinal associations between falls and future risk of cognitive decline, the Motoric Cognitive Risk syndrome and dementia: the Einstein Ageing Study. Age and Ageing, 2022, 51, .	1.6	11
290	Realâ€world assessment of the relationship between migraineâ€related disability and healthcare costs in the United States. Headache, 2022, 62, 473-481.	3.9	11
291	How useful is the HIT-6â,,¢ for measuring headache-related disability?. Nature Clinical Practice Neurology, 2006, 2, 70-71.	2.5	10
292	How Well Does the ICHD 3 (Beta) Help in Real-Life Migraine Diagnosis and Management?. Current Pain and Headache Reports, 2016, 20, 66.	2.9	10
293	Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study. Headache, 2021, 61, 103-116.	3.9	10
294	Mentally Challenging Occupations Are Associated With More Rapid Cognitive Decline at Later Stages of Cognitive Aging. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2021, 76, 671-680.	3.9	10
295	Efficacy of erenumab in chronic migraine patients with and without ictal allodynia. Cephalalgia, 2021, 41, 1152-1160.	3.9	10
296	Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI. Neurology, 2022, 98, .	1.1	10
297	Cholesteryl ester transfer protein genotype modifies the effect of apolipoprotein $\hat{l}\mu4$ on memory decline in older adults. Neurobiology of Aging, 2016, 41, 200.e7-200.e12.	3.1	9
298	The Independent and Interactive Associations of Bilingualism and Sex on Cognitive Performance in Hispanics/Latinos of the Hispanic Community Health Study/Study of Latinos. Journal of Alzheimer's Disease, 2019, 71, 1271-1283.	2.6	9
299	Anxiety Sensitivity as a Risk Indicator for Anxiety, Depression, and Headache Severity in Women With Migraine. Headache, 2019, 59, 1212-1220.	3.9	9
300	Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant. Advances in Therapy, 2021, 38, 5209-5220.	2.9	9
301	Metabolic Syndrome and Smoking Are Associated with Future Development of Advanced Chronic Kidney Disease in Older Adults. CardioRenal Medicine, 2016, 6, 108-115.	1.9	8
302	American Headache Society Survey About Urgent and Emergency Management of Headache Patients. Headache, 2018, 58, 1389-1396.	3.9	8
303	Neuropsychological latent classes at enrollment and postmortem neuropathology. Alzheimer's and Dementia, 2019, 15, 1195-1207.	0.8	8
304	Migraine day frequency in migraine prevention: longitudinal modelling approaches. BMC Medical Research Methodology, 2019, 19, 20.	3.1	8
305	The Association of Changes in Pain Acceptance and Headache-Related Disability. Annals of Behavioral Medicine, 2019, 53, 686-690.	2.9	8
306	Introduction of a smartphone based behavioral intervention for migraine in the emergency department. General Hospital Psychiatry, 2021, 69, 12-19.	2.4	8

#	Article	IF	Citations
307	Head Computed tomography during emergency department treat-and-release visit for headache is associated with increased risk of subsequent cerebrovascular disease hospitalization. Diagnosis, 2021, 8, 199-208.	1.9	8
308	Doseâ€response relationship between lateâ€life physical activity and incident dementia: A pooled analysis of 10 cohort studies of memory in an international consortium. Alzheimer's and Dementia, 2022, , .	0.8	8
309	Migraine: A "Woman's Disease?― Women and Health, 1999, 28, 79-99.	1.0	7
310	Assessing disability using the migraine disability assessment questionnaire. Expert Review of Neurotherapeutics, 2003, 3, 317-325.	2.8	7
311	Sumatriptan Iontophoretic Transdermal System Reduces Treatmentâ€Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline – Results From a Randomized Controlled Trial. Headache, 2015, 55, 1124-1132.	3.9	7
312	Primary headache: What's stress got to do with it?. Cephalalgia, 2015, 35, 844-849.	3.9	7
313	Qualitative Change in Migraine Prevention?. Headache, 2018, 58, 1092-1095.	3.9	7
314	Assessing diagnostic error in cerebral venous thrombosis via detailed chart review. Diagnosis, 2019, 6, 361-367.	1.9	7
315	Evaluating Mean Level and Withinâ€Person Consistency in Migraine Pain Intensity and Migraineâ€Related Disability for AVPâ€825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial. Headache, 2019, 59, 1002-1013.	3.9	7
316	Relationship Between Treatment Initiation and Healthcare Costs in Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 68, 1575-1585.	2.6	7
317	Visual memory tests enhance the identification of amnestic MCI cases at greater risk of Alzheimer's disease. International Psychogeriatrics, 2019, 31, 997-1006.	1.0	7
318	Cognition and Daily Functioning: Results from the Hispanic Community Health Study/Study of Latinos (SOL) and Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA). Journal of Alzheimer's Disease, 2020, 77, 1267-1278.	2.6	7
319	UDSNB 3.0 Neuropsychological Test Norms in Older Adults from a Diverse Community: Results from the Einstein Aging Study (EAS). Journal of Alzheimer's Disease, 2021, 83, 1665-1678.	2.6	7
320	The migraine signature study: Methods and baseline results. Headache, 2021, 61, 462-484.	3.9	7
321	Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study. Journal of Headache and Pain, 2022, 23, 22.	6.0	7
322	Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults. Neurology, 2022, 98, .	1.1	7
323	Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers. Neurobiology of Aging, 2017, 58, 239.e1-239.e7.	3.1	6
324	A Birth Cohort Analysis of Amnestic Mild Cognitive Impairment Incidence in the Einstein Aging Study (EAS) Cohort. Journal of Alzheimer's Disease, 2019, 70, S271-S281.	2.6	6

#	Article	IF	CITATIONS
325	Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials. Health and Quality of Life Outcomes, 2019, 17, 171.	2.4	6
326	DFN-02, Sumatriptan 10Âmg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment. CNS Drugs, 2019, 33, 375-382.	5.9	6
327	Education and the moderating roles of age, sex, ethnicity and apolipoprotein epsilon 4 on the risk of cognitive impairment. Archives of Gerontology and Geriatrics, 2020, 91, 104112.	3.0	6
328	A Latent Transition Analysis Model to Assess Change in Cognitive States over Three Occasions: Results from the Rush Memory and Aging Project. Journal of Alzheimer's Disease, 2020, 73, 1063-1073.	2.6	6
329	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura. Journal of Pain Research, 2021, Volume 14, 2529-2542.	2.0	6
330	A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults. Cephalalgia Reports, 2021, 4, 251581632110079.	0.7	6
331	Response to Mindfulness-Based Cognitive Therapy Differs Between Chronic and Episodic Migraine. Neurology: Clinical Practice, $2021, 11, 194-205$ .	1.6	6
332	Evaluating the clinical utility of the patientâ€identified most bothersome symptom measure from PROMISEâ€2 for research in migraine prevention. Headache, 2022, 62, 690-699.	3.9	6
333	Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis. Pain and Therapy, 2022, 11, 701-712.	3.2	6
334	Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. Journal of Headache and Pain, 2022, 23, 50.	6.0	6
335	The Site of Common Side Effects of Sumatriptan. Headache, 1997, 37, 289-290.	3.9	5
336	Headache: triumphs in translational research. Lancet Neurology, The, 2005, 4, 11-12.	10.2	5
337	Migraine and cardiovascular disease: is there a link?. Nature Clinical Practice Neurology, 2007, 3, 74-75.	2.5	5
338	Progress in headache mechanisms and management. Nature Reviews Neurology, 2011, 7, 67-68.	10.1	5
339	Evaluation of the 6â€item Identify Chronic Migraine screener in a large medical group. Headache, 2021, 61, 335-342.	3.9	5
340	Between and withinâ€woman differences in the association between menstruation and migraine days. Headache, 2021, 61, 430-437.	3.9	5
341	Potassium channel openers â€" novel triggers of aura and migraine. Nature Reviews Neurology, 2021, 17, 397-398.	10.1	5
342	Cerebrovascular disease hospitalizations following emergency department headache visits: A nested case–control study. Academic Emergency Medicine, 2021, , .	1.8	5

#	Article	IF	CITATIONS
343	Leveraging machine learning predictive biomarkers to augment the statistical power of clinical trials with baseline magnetic resonance imaging. Brain Communications, 2021, 3, fcab264.	3.3	5
344	Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study. Headache, 2022, 62, 755-765.	3.9	5
345	Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1 <sup>st</sup> edition. Cephalalgia, 2022, 42, 1099-1115.	3.9	5
346	Headache as a Real Disease. Headache, 2008, 48, 707-710.	3.9	4
347	The social impact and burden of headache. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 23-32.	1.8	4
348	Abdominal obesity is a risk factor for dysexecutive function in chronic kidney disease. Preventive Medicine Reports, 2016, 4, 128-133.	1.8	4
349	Subjective Cognitive Decline Prediction of Mortality: Results from the Einstein Aging Study. Journal of Alzheimer's Disease, 2018, 66, 239-248.	2.6	4
350	Predicting the Future of Migraine Attack Prediction. Headache, 2020, 60, 2125-2128.	3.9	4
351	Factors associated with hospitalization for ischemic stroke and TIA following an emergency department headache visit. American Journal of Emergency Medicine, 2021, 46, 503-507.	1.6	4
352	Measuring headache day severity using multiple features in daily diary designs. Cephalalgia, 2022, 42, 53-62.	3.9	4
353	Reliabilities of Intra-Individual Mean and Intra-Individual Variability of Self-Reported Pain Derived From Ecological Momentary Assessments: Results From the Einstein Aging Study. Journal of Pain, 2022, 23, 616-624.	1.4	4
354	Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials. Journal of Heada and Pain, 2022, 23, 23.	ac <b>b</b> eo	4
355	Individuals with both higher recent negative affect and physical pain have higher levels of C-reactive protein. Brain, Behavior, & Immunity - Health, 2022, 21, 100431.	2.5	4
356	Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials. Journal of Medical Economics, 2022, 25, 630-639.	2.1	4
357	Moving Forward – Essential Questions for the Next 10 Years. Headache, 2009, 49, S43-6.	3.9	3
358	P2-314: PERCEIVED STRESS AND RISK OF DEMENTIA IN OLDER ADULTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT. , 2014, 10, P594-P594.		3
359	Regional versus general anaesthesia for improved cognitive function after procedures other than cardiac surgery or neurosurgery in adult and paediatric patients. The Cochrane Library, 2016, 2016, .	2.8	3
360	Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraineâ€Associated Nausea and Prior Triptan Use on Efficacy. Headache, 2017, 57, 756-765.	3.9	3

#	Article	lF	Citations
361	Migraine Progression: A Systematic Review. An Editorial Comment. Headache, 2019, 59, 974-976.	3.9	3
362	Repeated Spiral Drawings in Essential Tremor: a Possible Limb-Based Measure of Motor Learning. Cerebellum, 2019, 18, 178-187.	2.5	3
363	Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis. Pain and Therapy, 2020, 9, 683-694.	3.2	3
364	The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine. Pain and Therapy, 2020, 9, 695-707.	3.2	3
365	Headache complexity (number of symptom features) differentiates post-traumatic from non-traumatic headaches. Cephalalgia, 2021, 41, 582-592.	3.9	3
366	Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial. Journal of Pain Research, 2021, Volume 14, 549-560.	2.0	3
367	Re-evaluation of psychometric evidence and update of normative data for the Test of Practical Judgment. Clinical Neuropsychologist, 2021, , 1-24.	2.3	3
368	Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies. Cephalalgia, 2021, 41, 033310242110289.	3.9	3
369	A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN. Journal of Headache and Pain, 2021, 22, 101.	6.0	3
370	Combining patient reported outcomes and EHR data to understand population level treatment needs: correcting for selection bias in the migraine signature study. Journal of Patient-Reported Outcomes, 2021, 5, 132.	1.9	3
371	Psychiatric Sequelae Following Whiplash Injury: A Systematic Review. Frontiers in Psychiatry, 2022, 13, 814079.	2.6	3
372	P3-213: Estimating episodic memory within-subject decline among nondemented older adults: Results from the einstein aging study (EAS)., 2015, 11, P714-P714.		2
373	P2â€609: MOTORIC COGNITIVE RISK SYNDROME: A GAIT OR COGNITIVE SYNDROME?. Alzheimer's and Dementia, 2018, 14, P972.	0.8	2
374	Evolution of the Research Literature and the Scientific Community of Alzheimer's Disease from 1983-2017: A 35-Year Survey. Journal of Alzheimer's Disease, 2020, 75, 1105-1134.	2.6	2
375	Prevalence of incidental brain MRI findings of clinical relevance in a diverse Hispanic/Latino population. Journal of Neuroimaging, 2021, 31, 1166-1175.	2.0	2
376	Do behavioral treatments work for migraine prevention?. Headache, 2022, 62, 402-404.	3.9	2
377	Headache in the elderly. Journal of Back and Musculoskeletal Rehabilitation, 1998, 11, 3-17.	1.1	1
378	Disease Management of Migraine and the Importance of Stratified Care. Disease Management and Health Outcomes, 2003, 11, 379-388.	0.4	1

#	Article	IF	CITATIONS
379	Response: Coexisting Trigeminal Autonomic Cephalalgias and Hemicrania Continua. Headache, 2010, 50, 1218-1219.	3.9	1
380	Eager for better migraine therapies. Neurology, 2014, 83, 954-955.	1.1	1
381	P3-259: A brief dietary assessment predicts executive dysfunction in an elderly cohort: Results from the einstein aging study (EAS)., 2015, 11, P731-P732.		1
382	P1-362: Longitudinal Analysis of The Free and Cued Selective Reminding Test in Pre-Clinical and Clinical Alzheimer's Disease: Temporal Unfolding of Stages of Memory Impairment., 2016, 12, P568-P569.		1
383	P4â€235: Cognitive Decline and Effects of Sex, Education and Apolipoprotein E Genotype on Cognitive Performance in Diverse Ethnoâ€Cultural and Geographical Regions Internationally: The Cosmic Collaboration. Alzheimer's and Dementia, 2016, 12, P1119.	0.8	1
384	[ICâ€Pâ€127]: GRAY MATTER VOLUME AND THE MOTORIC COGNITIVE RISK SYNDROME: A MULTIâ€COHORT MR STUDY. Alzheimer's and Dementia, 2017, 13, P96.	0.8	1
385	Re: Placebo responses in device studies. Cephalalgia, 2018, 38, 1007-1008.	3.9	1
386	P3â€467: PROCESS OF IDENTIFYING A CLINICAL MODEL OF LATENT NEUROPSYCHOLOGICAL PROFILES IN COMMUNITYâ€DWELLING OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1298.	0.8	1
387	Comment: Noninvasive neurostimulation for migraine should be part of the general neurologist's therapeutic armamentarium. Neurology, 2018, 91, 167-167.	1.1	1
388	Cognitive leisure activities in later older adulthood may protect against accelerated rates of memory decline. Alzheimer's and Dementia, 2020, 16, e041512.	0.8	1
389	Diabetes, cognitive decline and mild cognitive impairment among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos (HCHSâ€SOL) investigation of cognitive aging results. Alzheimer's and Dementia, 2020, 16, e044601.	0.8	1
390	Variability in every day pain is associated with mild cognitive impairment (MCI): Results from the Einstein Aging Study (EAS). Alzheimer's and Dementia, 2020, 16, e045355.	0.8	1
391	Effect of Mentally Challenging Occupations on Incident Dementia Differs Between African Americans and Non-Hispanic Whites. Journal of Alzheimer's Disease, 2020, 75, 1405-1416.	2.6	1
392	Testing rimegepant for migraineâ€"time to revise the trial design? â€" Authors' reply. Lancet, The, 2020, 395, 1901-1902.	13.7	1
393	Author Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study. Neurology, 2021, 96, 683-684.	1.1	1
394	Author Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study. Neurology, 2021, 96, 686-686.	1.1	1
395	Development and psychometric evaluation of the Test of Practical Judgment alternate form (Form B). Applied Neuropsychology Adult, 2021, , 1-10.	1.2	1
396	The value of the patient perspective in understanding the full burden of migraine. Headache, 2021, 61, 985-987.	3.9	1

#	Article	IF	CITATIONS
397	What do people want to know about "Growing Up with Migraine� Results of a preference survey of people with lived experience to guide future research. Cephalalgia, 2021, , 033310242110385.	3.9	1
398	Latent Cognitive Class at Enrollment Predicts Future Cognitive Trajectories of Decline in a Community Sample of Older Adults. Journal of Alzheimer's Disease, 2021, 83, 641-652.	2.6	1
399	Under Treatment of High-Risk TIA Patients with Clopidogrel-Aspirin in the Emergency Setting. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 106145.	1.6	1
400	Emergency medicine physicians' perspectives on diagnostic accuracy in neurology: a qualitative study. Diagnosis, 2021, .	1.9	1
401	Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials. Headache, 2022, 62, 159-168.	3.9	1
402	Spreading Depression Marches On. Headache, 1990, 30, 741-741.	3.9	0
403	Chronic daily headache., 2002,, 955-972.		0
404	Combined prophylactic $\hat{A}$ -blocker and behavioural migraine management improves 30-day migraine outcomes compared with either strategy alone, or optimised acute treatment only. Evidence-Based Medicine, 2011, 16, 77-78.	0.6	0
405	Modifiable predictors of racial differences in gait velocity in an elderly urban cohort. Annals of the Rheumatic Diseases, 2011, 70, A93-A93.	0.9	0
406	P3-152: PAIN INTENSITY AND PAIN INTERFERENCE ARE ASSOCIATED WITH TRANSITIONS FROM COGNITIVE NORMALITY, AMNESTIC MCI (AMCI), AND DEMENTIA: RESULTS FROM THE EINSTEIN AGING STUDY (EAS). , 2014, 10, P684-P684.		0
407	P3-156: POOR RENAL FUNCTION IS ASSOCIATED WITH AMCI AT CROSS-SECTION: RESULTS FROM THE EINSTEIN AGING STUDY. , 2014, 10, P685-P686.		0
408	P3-167: PERCEIVED STRESS, PERSONALITY, AND RISK OF AMNESTIC MILD COGNITIVE IMPAIRMENT (AMCI): RESULTS FROM THE EINSTEIN AGING STUDY (EAS). , 2014, 10, P690-P690.		0
409	P3-181: Correlates of memory function in older adults: The importance of white matter hyperintensities and hippocampal volume., 2015, 11, P699-P700.		0
410	P3-111: Abdominal obesity is a risk factor for executive dysfunction in chronic kidney disease but not in otherwise healthy older adults., 2015, 11, P663-P663.		0
411	P4-104: Cross-sectional diagnostic validity of the memory binding test., 2015, 11, P815-P816.		0
412	P3-118: Perceived stress, ApoE status, and risk of amnestic mild cognitive impairment (aMCI): Results from the einstein aging study (EAS)., 2015, 11, P667-P667.		0
413	O3-02-03: Is dementia incidence declining? a birth cohort analysis of the einstein aging study (EAS) cohort, 1993-2014., 2015, 11, P220-P220.		0
414	P2-200: Identifying memory impairment and dementia in primary care settings., 2015, 11, P569-P569.		0

#	Article	IF	CITATIONS
415	O3-10-04: Performance on the memory binding test predicts incident aMCI and dementia: Results from the einstein aging study., 2015, 11, P242-P242.		O
416	P4-149: Stress and white matter hyperintensities in nondemented older adults., 2015, 11, P836-P836.		0
417	P1-022: Coping and distress and risk of amnestic mild cognitive impairment in older adults. , 2015, 11, P344-P345.		O
418	Exploring the impact of comorbid primary headaches and neck pain. Scandinavian Journal of Pain, 2015, 8, 23-24.	1.3	O
419	P4-363: Intensive Ambulatory Assessments are Feasible in Community Dwelling Adults Aged 70+: Results From the Einstein Aging Study (EAS). , 2016, 12, P1176-P1176.		O
420	2015 <i>Headache</i> Members' Choice Award. Headache, 2016, 56, 1088-1090.	3.9	0
421	[P3â€"355]: WHITE MATTER HYPERINTENSITIES MODIFY THE RELATIONSHIP BETWEEN HIPPOCAMPAL VOLUME AND VERBAL MEMORY IN OLDER ADULTS WITHOUT DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1091.	0.8	O
422	[P1–323]: SUBJECTIVE COGNITIVE DECLINE (SCD) PREDICTS MORTALITY IN A COMMUNITYâ€BASED ELDERLY COHORT: RESULTS FROM THE EINSTEIN AGING STUDY (EAS). Alzheimer's and Dementia, 2017, 13, P379.	0.8	0
423	[P2â€"466]: EFFECT OF THE APOLIPOPROTEIN E E2 (APOE2) ALLELE ON MEMORY DECLINE AND INCIDENCE AND TRANSITION TO ALZHEIMER's DISEASE (AD): RESULTS FROM THE EINSTEIN AGING STUDY (EAS). Alzheimer's and Dementia, 2017, 13, P819.	0.8	O
424	P3â€555: HEALTHâ€RELATED QUALITY OF LIFE MEASURES FROM SFâ€36 HEALTH SURVEY PREDICT INCIDENT DEMENTIA IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1335.	0.8	0
425	P4â€163: HEALTH CARE COSTS AMONG NEWLY DIAGNOSED ALZHEIMER'S DISEASE PATIENTS IN A REALâ€WORL ADMINISTRATIVE CLAIMS DATABASE. Alzheimer's and Dementia, 2018, 14, P1501.	D 0.8	O
426	P2â€598: THE RELATIVE FREQUENCY OF DEMENTIAâ€RELATED DIAGNOSES AMONG INCIDENT ALZHEIMER'S DISEASE PATIENTS COMPARED WITH CONTROLS IN COMMERCIAL AND MEDICARE SUPPLEMENTAL DATABASES. Alzheimer's and Dementia, 2018, 14, P967.	0.8	0
427	P3â€337: GENDER EFFECTS ON GRAY MATTER NETWORKS ASSOCIATED WITH THE MOTORIC COGNITIVE RISK SYNDROME: A MULTI OHORT MRI STUDY. Alzheimer's and Dementia, 2018, 14, P1211.	0.8	O
428	P1â€510: RETRIEVAL SPEED CAN PREDICT MILD COGNITIVE IMPAIRMENT PRIOR TO DIAGNOSIS: RESULTS FROM THE EINSTEIN AGING STUDY. Alzheimer's and Dementia, 2018, 14, P526.	0.8	0
429	P4â€154: DEPRESSIVE SYMPTOMS PREDICT INCIDENT DEMENTIA IN A COMMUNITY SAMPLE OF OLDER ADULTS: RESULTS FROM THE EINSTEIN AGING STUDY. Alzheimer's and Dementia, 2018, 14, P1498.	0.8	O
430	P1â€315: PREVALENCE OF DIAGNOSED SYMPTOMS PRECEDING ALZHEIMER'S DISEASE DIAGNOSIS AMONG TREATED AND UNTREATED ALZHEIMER'S DISEASE PATIENTS WITH COMMERCIAL AND MEDICARE SUPPLEMENTAL INSURANCE. Alzheimer's and Dementia, 2018, 14, P412.	0.8	O
431	P4â€119: COGNITIVE PROFILES IN OLD AGE IN RELATION TO INCIDENT ALLâ€CAUSE DEMENTIA AND ALZHEIMER' DISEASE. Alzheimer's and Dementia, 2018, 14, P1484.	S 0.8	O
432	P2â€493: RETRIEVAL SPEED AND LEVEL OF PERFORMANCE ON THE CUEDâ€RECALL RETRIEVAL SPEED TASK CAN PREDICT ONSET OF COGNITIVE IMPAIRMENT: RESULTS FROM THE EINSTEIN AGING STUDY. Alzheimer's and Dementia, 2018, 14, P918.	0.8	0

#	Article	IF	CITATIONS
433	Estimation of multi-state models with missing covariate values based on observed data likelihood. Communications in Statistics - Theory and Methods, 2019, 48, 5733-5747.	1.0	0
434	Spotlight on headache. Neurology: Clinical Practice, 2019, 9, 182-182.	1.6	0
435	AFFECTIONATE PHYSICAL TOUCH MITIGATES PAIN AND EMOTIONAL DISTRESS IN OLDER ADULTS. Innovation in Aging, 2019, 3, S810-S810.	0.1	0
436	THE APOE-ε4 ALLELE AND AGE SYNERGISTICALLY DRIVE DISEASE PROGRESSION IN ALZHEIMER'S DISEASE. Innovation in Aging, 2019, 3, S943-S943.	0.1	0
437	Variability in working memory performance on mobile devices is sensitive to mild cognitive impairment: Results from the Einstein Aging Study. Alzheimer's and Dementia, 2020, 16, e039960.	0.8	O
438	Prediction of longitudinal clinical outcomes of MCI population using Alzheimer's AT[N] biomarker profiling: Can machine learning methods improve our predictions?. Alzheimer's and Dementia, 2020, 16, e041125.	0.8	0
439	Daily functioning and cognition: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and Study of Latinosâ€Investigation of Neurocognitive Aging (SOLâ€INCA). Alzheimer's and Dementia, 2020, 16, e044165.	0.8	O
440	Cardiovascular and stroke risk, cognitive change, and mild cognitive impairment: Results from the HCHS/SOL and SOLâ€NCA. Alzheimer's and Dementia, 2020, 16, e044166.	0.8	0
441	Subjective cognitive decline is associated with neurocognition in the SOLâ€INCA study. Alzheimer's and Dementia, 2020, 16, e044167.	0.8	O
442	Optimizing the memory binding test for detection of aMCI and dementia. Alzheimer's and Dementia, 2020, 16, e044596.	0.8	0
443	Comparing versions of the memory binding test: Predictive validity for incident aMCI and incident dementia. Alzheimer's and Dementia, 2020, 16, e044612.	0.8	O
444	Cumulative effects of sleep quality on risk for incident mild cognitive impairment (MCI): Results from the Einstein Aging Study (EAS) cohort. Alzheimer's and Dementia, 2020, 16, e044861.	0.8	0
445	Abstract P257: Cost-Effectiveness of Advanced Neuroimaging for Transient & Minor Neurological Events in the Emergency Department. Stroke, 2021, 52, .	2.0	O
446	Author Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study. Neurology, 2021, 96, 684-685.	1.1	0
447	Naturalistic assessment of patterns and predictors of acute headache medication use among women with comorbid migraine and overweight or obesity. Translational Behavioral Medicine, 2021, 11, 1495-1506.	2.4	0
448	Abstract P349: Psychosocial Resources and Stressors Associated With Cognition Among Middle-Aged and Older Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos Sociocultural Ancillary Study. Circulation, 2019, 139, .	1.6	0
449	Is it time to use predictive models to boost power of Alzheimer's disease clinical trials? A postâ€hoc analysis of phase 3 solanezumab trials. Alzheimer's and Dementia, 2020, 16, e043022.	0.8	0
450	Evaluating Daily Versus Global Stress Appraisals' Sensitivity to Mild Cognitive Impairment. Innovation in Aging, 2020, 4, 598-599.	0.1	0

#	Article	IF	CITATIONS
451	Activity Diversity in Detecting Ambulatory Cognitive Deficits. Innovation in Aging, 2020, 4, 599-599.	0.1	0
452	Reliabilities of mean and variability of ambulatory pain among community dwelling older adults. Innovation in Aging, 2021, 5, 885-885.	0.1	0
453	Migraine: primary care challenges in diagnosis and treatment. Introduction. American Journal of Medicine, 2005, 118 Suppl 1, 1S-2S.	1.5	0
454	Treatment Patterns and Unmet Needs in the Acute Treatment of Migraine. Journal of Family Practice, 2020, 69, S1-S7.	0.2	0
455	Abstract 2292: Dipyridamole Induced Headache Indicates Lower Recurrence Risk in Secondary Prevention of Ischemic Stroke. Stroke, 2012, 43, .	2.0	O
456	Concordance Between Self-Reported Medical Diagnosis of Mild Cognitive Impairment/Dementia and Neurocognitive Function Among Middle-Aged and Older Hispanic/Latino Adults: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA). Journal of Alzheimer's Disease, 2022, , 1-11.	2.6	O
457	0322 sleep disordered breathing and MRI makers of brain aging in the Hispanic Community Health Study/Study of Latinos. Sleep, 2022, 45, A145-A145.	1.1	O
458	207†OnabotA for CM: benefits beyond headache-day reduction. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A73.1-A73.	1.9	0